4 completed, 2 recruiting, 2 withdrawn, 1 not yet recruiting. 10 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Recruiting 2, Withdrawn 2, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Craving: new trials by email Literature Review of Craving trials Research Report on Craving
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving Cannabidiol (CBD), Placebo - Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 105 | 2026-10-21 | 2026-11-03 |
| Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use Endotoxin, Placebo saline - Alcohol Use Disorder, Inflammatory Response | Phase 2 | Not yet recruiting | University of California, Los Angeles | 64 | 2026-09-01 | 2026-08-28 |
| Probenecid Administration for Alcohol Craving and Consumption Probenecid Oral Tablet, Placebo Oral Tablet - Alcohol Use Disorder (AUD), Alcohol Consumption | Phase 2 | Recruiting | Brown University | 120 | 2026-03-14 | 2026-03-17 |
| An Inflammatory Challenge Using Endotoxin Placebo, Endotoxin - Alcohol Use Disorder, Inflammatory Response | Phase 2 | Completed | University of California, Los Angeles | 20 | 2021-10-19 | 2025-05-01 |
| Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder CBOT + TAU, Sham + TAU - Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe | Phase 2 | Unknown | Evon Medics LLC | 190 | 2021-03-26 | 2021-08-06 |
| The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial Suvorexant 20 mg - Sleep Disturbance, Craving | Phase 2 / Phase 3 | Completed | Milton S. Hershey Medical Center | 28 | 2019-07-01 | 2024-02-13 |
| The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students Ashwagandha, Placebo - Stress, Sleep | Phase 2 | Completed | University of Colorado, Colorado Springs | 60 | 2019-05-29 | 2022-06-24 |
| Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia Active rTMS (20Hz), Sham rTMS - Tobacco Use Disorder, Schizophrenia | Phase 2 | Withdrawn | Centre for Addiction and Mental Health | 2018-07-01 | 2023-09-06 | |
| Minocycline for Alcohol Use Disorder Minocycline, Sugar pill - Alcohol Use Disorder, Inflammation | Phase 1 / Phase 2 | Withdrawn | University of California, Los Angeles | 2018-01-15 | 2019-01-24 | |
| Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues Dulaglutide, 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) - Glucagon-like Peptide-1, Smoking Cessation | Phase 2 | Completed | University Hospital, Basel, Switzerland | 256 | 2017-06-26 | 2022-09-13 |
Alcoholism (5) · Alcohol Drinking (2) · Alcohol Abstinence (1) · Body Weight Changes (1) · Cognition Disorders (1) · Consciousness Disorders (1) · Inflammation (1) · Lymphoma, Follicular (1) · Opioid-Related Disorders (1) · Parasomnias (1) · Schizophrenia (1) · Smoking (1) · Smoking Cessation (1) · Substance Withdrawal Syndrome (1) · Tobacco Use Disorder (1)
Mental Disorders (8) · Chemically-Induced Disorders (7) · Substance-Related Disorders (7) · Alcohol-Related Disorders (5) · Behavior (5) · Drinking Behavior (3) · Pathological Conditions, Signs and Symptoms (3) · Nervous System Diseases (2) · Neurocognitive Disorders (2) · Signs and Symptoms (2) · Body Weight (1) · Health Behavior (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1)
Endotoxins (2) · Sodium Chloride (2) · Ashwagandha (1) · Cannabidiol (1) · Glycerol (1) · Lipopolysaccharides (1) · Minocycline (1) · Probenecid (1) · Saline Solution (1) · Sugars (1) · dulaglutide (1) · salicylhydroxamic acid (1) · suvorexant (1)
University of California, Los Angeles (3) · Brown University (1) · Centre for Addiction and Mental Health (1) · Evon Medics LLC (1) · Johns Hopkins University (1) · Milton S. Hershey Medical Center (1) · University Hospital, Basel, Switzerland (1) · University of Colorado, Colorado Springs (1)
United States (6) · Switzerland (1)
Lara Ray, PhD (2) · Bettina Winzeler, Dr. (1) · Carolina Haass-Koffler, PharmD, PhD (1) · David Woliinsky, MD (1) · Edwin Chapman, MD (1) · Evaristus A Nwulia, MD (1) · Marc Fishman, MD (1) · Margaret Harris, PhD (1) · Mark Johnson, MD (1) · Michael Serlin, MD (1) · Tanya Alim, MD (1) · Venkatesh Basappa Krishnamurthy, MD (1)
PMID 22464727, PMID 29486960, PMID 35984870, PMID 35984871, PMID 36874396, PMID 37081574, PMID 37991022, PMID 38264360, PMID 38371479, PMID 40037282
2017 (1), K01AA026005 (1), K24AA025704 (1), R44DA049616 (1)